Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICAR19 CAR-T Cells in CD19+ Leukemia and Lymphoma
NCT03383952Phase 1Recruiting
- Start
- Mar 2017
- Primary completion
- Dec 2020
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ICAR19 CAR-T cells in B-cell leukemia (BCL) and B cell lymphoma. Primary endpoint: Measure the safety of ICAR19 CAR-T cells at 2 years. Started Mar 2017; status: recruiting.
02
Drugs
ICAR19 CAR-T cells
03
Conditions
B-cell leukemia (BCL)B cell lymphoma
Beyond the preview
Go deeper on NCT03383952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03383952.